Market Trends of Europe Breast Cancer Screening Tests Industry
Mammograms Expected to Hold a Major Share in the Europe Breast Cancer Screening Test Market Over The Forecast Period
Mammograms are the most commonly utilized tests for detecting breast cancer. Mammography, recognized as the gold standard technique, plays a crucial role in early breast cancer detection and significantly improves treatment outcomes.
In Europe, governments and healthcare organizations are actively ensuring that women aged 50 to 75 have access to mammography screenings. This push is driving up the demand for mammography services. Concurrently, laboratory blood tests and various imaging tests are also witnessing a surge in popularity. For instance, in January 2023, according to the Department of Health and Social Care, NHS England, the government allocated GBP 10 million (USD 12.2 million) to deliver 29 new breast cancer screening units to speed up breast cancer diagnosis and treatment. Thus, such government initiatives are likely to increase mammogram adoption, driving the segment growth.
The increase in strategic initiatives such as agreements and partnerships to provide mammograms in the European region is expected to propel the segment growth over the forecast period. For instance, in March 2024, Lunit signed a supply contract with TeleDiag in France and the Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro; LPCC). These contracts provide AI-driven radiology solutions: chest X-ray detection in collaboration with TeleDiag and breast cancer detection with LPCC. Additionally, Lunit has entered into another agreement with the central region branch of LPCC, supplying its FDA-cleared and CE-marked AI solution for mammography analysis, known as Lunit INSIGHT MMG. Such an agreement will increase the supply of mammograms in the market owing to increasing demand, likely to contribute to the segment growth.
Furthermore, market players' new product introductions are poised to boost the segment's growth. For instance, in February 2024, Fujifilm unveiled its cutting edge mammography technology, Amulet Sophinity, at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria, from February 28 to March 3, 2024. As highlighted in a press release, this groundbreaking technology aimed to boost the accuracy and convenience of breast cancer diagnoses, all while prioritizing patient comfort and upholding superior image quality. Such technological strides in mammograms are poised to spur demand and propel segment growth throughout the forecast period.
Consequently, due to these factors including heightened government initiatives promoting breast screening and a surge in clinical trials for advanced mammograms, the segment is poised for substantial growth in the coming years.
Germany is Expected to Hold a Significant Share in the Europe Breast Cancer Screening Tests Market Over the Forecast Period
Germany is poised to command a substantial share of the market owing to factors such as the high burden of breast cancer and rising awareness initiatives, increasing development and product launches for breast cancer screening.
The awareness campaigns in the country are anticipated to accelerate market growth over the projected period. For instance, In a bid to bolster awareness for breast cancer prevention, Munich's Königsplatz was illuminated in pink from October 11 to 13, 2023, as part of Estée Lauder Companies' Breast Cancer Campaign 2023. Such awareness initiatives are expected to increase the utility of breast cancer screening in the country, thereby augmenting the market growth during the projected period.
Several initiatives taken to increase access to mammography in Germany for women are likely to contribute to market growth. For instance, in Germany, women aged 50 to 75 are entitled to a complimentary mammogram biennially, which ceases on their 76th birthday. The primary goal of the screening is to identify breast cancer at its earliest stage, thereby enhancing treatment efficacy and boosting recovery odds. Thus, such initiatives will support the adoption of mammography for breast cancer diagnosis is anticipated to propel the market growth over the projected period.
Further, increasing funding for the development of breast cancer is expected to propel the market growth over the forecast period. For instance, in November 2024, Vara, a Berlin-based enterprise utilizing AI to enhance breast cancer screenings, announced it has secured GBP 8.2 million (USD 8.8 million) to support its expansion across Europe. The company's AI-powered software aims to improve the accuracy and efficiency of breast cancer detection. Such funding initiatives that provide access to these breast cancer screening tests are likely to boost its demand, contributing to the market growth.
Therefore, owing to factors such as the rising launches of screening tests by market players and increasing awareness initiatives in the country, the country is expected to witness growth during the forecast period.
